Repositioning Candidate Details
| Candidate ID: | R1444 |
| Source ID: | DB12340 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Navitoclax |
| Synonyms: | Navitoclax |
| Molecular Formula: | C47H55ClF3N5O6S3 |
| SMILES: | [H][C@@](CCN1CCOCC1)(CSC1=CC=CC=C1)NC1=C(C=C(C=C1)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC2=C(CCC(C)(C)C2)C2=CC=C(Cl)C=C2)CC1)S(=O)(=O)C(F)(F)F |
| Structure: |
|
| DrugBank Description: | Navitoclax has been used in trials studying the treatment and basic science of Solid Tumors, Non-Hodgkin's Lymphoma, EGFR Activating Mutation, Chronic Lymphoid Leukemia, and Hematological Malignancies, among others. Navitoclax is an orally bioavailable small molecule inhibitor of Bcl-2 family proteins. It is a substance being studied in the treatment of lymphomas and other types of cancer. It blocks some of the enzymes that keep cancer cells from dying. |
| CAS Number: | 923564-51-6 |
| Molecular Weight: | 974.613 |
| DrugBank Indication: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Navitoclax targets the Bcl-2 family of proteins, the major negative regulators of apoptosis. The Bcl-2 proteins, including Bcl-2, Bcl-xL, and Bcl-w, work by binding to two other groups of proteins-the executioners (Bax, Bak) that actually start the destruction pathway, and the sentinel proteins. Cancer cells frequently overexpress the Bcl-2-like proteins, and thus, when they sustain DNA damage-from radiation, for example-they continue growing. Preventing the Bcl-2-like proteins from binding to the executioners might be able to trigger cell death in the tumor. |
| Targets: | Apoptosis regulator Bcl-2; Bcl-2-like protein 2; Bcl2 antagonist of cell death |
| Inclusion Criteria: | Therapeutic strategy associated |
